Search Results 61-70 of 16849 for CLL

  1. A Study to Assess the Effectiveness and Safety of Ublituximab in combination with Umbralisib and Venetoclax (U2-V) Compared to Ublituximab and Umbralisib (U2) in Subjects with Chronic Lymphocytic Leukemia (CLL) - Mayo Clinic

    ... Chronic Lymphocytic Leukemia (CLL). Print details. Share; Facebook · Twitter. Overview; Participation eligibility; Participating Mayo Clinic info; More ...

  2. Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy - Mayo Clinic

    About this study. This phase II trial studies the side effects and how well ibrutinib works in treating patients with chronic lymphocytic leukemia who ...

  3. Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion - Mayo Clinic

    ... chronic lymphocytic leukemia (CLL) with 17p deletion. An increased rate of deaths and serious adverse events (SAEs) among participants with front-line CLL ...

  4. Targeted Drug with Chemotherapy Combo Offers Longer Life to Patients with B-cell Cancers - Mayo Clinic News Network

    ... chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), an interim analysis has closed the international HELIOS phase III clinical trial.

  5. Mayo Clinic-Led Researchers Confirm Gene Variants Associated With The Most Common Adult Leukemia

    A national team of researchers led by Mayo Clinic has found that patients with chronic lymphocytic leukemia (CLL) are more likely to have similar DNA ...

  6. A Study Comparing Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients with Chronic Lymphocytic Leukemia - Mayo Clinic

    Giving ibrutinib, obinutuzumab and venetoclax may work better in treating patients with chronic lymphocytic leukemia. Participation eligibility. Participant ...

  7. Leukemia Clinical Trials - Mayo Clinic Research

    ... chronic lymphocytic leukemia (CLL) with 17p deletion. An increased rate of deaths and serious adverse events (SAEs) among participants with front-line CLL ...

  8. Clinical trials - Oncology (Medical)

    The purpose of this study is to determine if a new drug combination, pirtobrutinib and venetoclax, will help Chronic Lymphocytic Leukemia (CLL) or Small ...

  9. Hematology - Clinical trials

    Anticipated time on study is up to 5 years. A Study of Hematopoiesis in Patients with Monoclonal B Cell Lymphocytosis (MBL), B-Chronic Lymphocytic Leukemia (CLL) ...

  10. Acalabrutinib (oral route) - Side effects & dosage - Mayo Clinic

    This medicine is also used to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This medicine is available only with your ...